SCHEMBL24253585

SCHEMBL24253585

CC(C)c1nc2cnccc2cc1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.39
PDGFRB P09619 3/20 0.36
PDGFRA P16234 3/20 0.36
EGFR P00533 2/20 0.36
RPS6KA3 P51812 1/20 0.36
MAP4K4 O95819 1/20 0.36
MINK1 Q8N4C8 1/20 0.36
TNIK Q9UKE5 1/20 0.36
PRKCZ Q05513 1/20 0.34
MELK Q14680 1/20 0.34
LATS1 O95835 5/20 0.34
LATS2 Q9NRM7 4/20 0.34
MAPK10 P53779 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
STAT3 P40763 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
ALOX5 P09917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24868087 0.86 DAO (0.39) DAOPDGFRBPDGFRAEGFRRPS6KA3
SCHEMBL13233191 0.81 RPS6KA3 (0.36) RPS6KA3MAP4K4MINK1TNIKPRKCZ
SCHEMBL13263764 0.81 MAP4K4 (0.36) MAP4K4MINK1TNIKPRKCZLATS1
SCHEMBL6004354 0.77 HPGD (0.58) DAOPDGFRBPDGFRAEGFRMAP4K4
SCHEMBL2968593 0.77 ALDH1A1 (0.58) MAPK10KDM4EALDH1A1GAAHPGD
SCHEMBL24249190 0.76 RPS6KA3 (0.42) DAOPDGFRBPDGFRARPS6KA3MAP4K4
SCHEMBL15423527 0.74 LATS1 (0.36) PRKCZLATS1LATS2KDM4E
SCHEMBL28149552 0.73 DAO (0.42) DAOPDGFRBPDGFRAEGFRMAP4K4
SCHEMBL24248635 0.72 EGFR (0.37) EGFR
SCHEMBL12026453 0.71 MAP4K4 (0.39) MAP4K4MINK1TNIKPRKCZLATS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 DAO 4543/4885PDGFRB 3485/4885PDGFRA 3870/4885
US-20230008867-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 DAO 4354/4885PDGFRB 4048/4885PDGFRA 4296/4885
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 DAO 4354/4885PDGFRB 4048/4885PDGFRA 4296/4885
US-20230027684-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 DAO 4543/4885PDGFRB 3485/4885PDGFRA 3870/4885
US-20230009712-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 DAO 4543/4885PDGFRB 3485/4885PDGFRA 3870/4885
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 DAO 4163/4885PDGFRB 4020/4885PDGFRA 4174/4885
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 DAO 4543/4885PDGFRB 3485/4885PDGFRA 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.